HNI Corporation (HNI)
NYSE: HNI · Real-Time Price · USD
43.30
-0.31 (-0.71%)
Aug 8, 2025, 3:26 PM - Market open
Verve Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 28, 2025 | Dec '24 Dec 28, 2024 | Dec '23 Dec 30, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Jan '21 Jan 2, 2021 | 2016 - 2020 |
| 2,582 | 2,526 | 2,434 | 2,362 | 2,184 | 1,955 | Upgrade | |
Revenue Growth (YoY) | -0.83% | 3.80% | 3.06% | 8.12% | 11.71% | -12.97% | Upgrade |
Cost of Revenue | 1,513 | 1,488 | 1,485 | 1,518 | 1,419 | 1,234 | Upgrade |
Gross Profit | 1,069 | 1,038 | 949.2 | 843.7 | 765 | 721.2 | Upgrade |
Selling, General & Admin | 751.2 | 736.1 | 694.6 | 644.7 | 596.1 | 560.9 | Upgrade |
Research & Development | 53.6 | 53.6 | 47.2 | 47.8 | 39.4 | 35.3 | Upgrade |
Operating Expenses | 834.7 | 820.6 | 771.9 | 723.4 | 665.6 | 620.5 | Upgrade |
Operating Income | 234 | 217.8 | 177.3 | 120.3 | 99.4 | 100.7 | Upgrade |
Interest Expense | -23.8 | -27.2 | -25.5 | -8.8 | -7.2 | -7 | Upgrade |
Currency Exchange Gain (Loss) | - | - | - | - | - | -0.4 | Upgrade |
Other Non Operating Income (Expenses) | 0.2 | - | - | - | - | -0.1 | Upgrade |
EBT Excluding Unusual Items | 210.4 | 190.6 | 151.8 | 111.5 | 92.2 | 93.2 | Upgrade |
Merger & Restructuring Charges | -11.6 | -11.2 | -54.4 | -14.5 | -8.1 | -38.8 | Upgrade |
Impairment of Goodwill | - | - | -27.6 | - | -5.8 | - | Upgrade |
Gain (Loss) on Sale of Investments | -0.1 | -0.1 | -1.6 | -1 | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -6.4 | - | - | 50.4 | - | - | Upgrade |
Asset Writedown | - | - | -3.4 | - | - | - | Upgrade |
Pretax Income | 192.3 | 179.3 | 64.8 | 146.4 | 78.3 | 54.4 | Upgrade |
Income Tax Expense | 44.3 | 39.8 | 15.6 | 22.5 | 18.5 | 12.5 | Upgrade |
Earnings From Continuing Operations | 148 | 139.5 | 49.2 | 123.9 | 59.8 | 41.9 | Upgrade |
Net Income | 148 | 139.5 | 49.2 | 123.9 | 59.8 | 41.9 | Upgrade |
Net Income to Common | 148 | 139.5 | 49.2 | 123.9 | 59.8 | 41.9 | Upgrade |
Net Income Growth | 29.60% | 183.54% | -60.29% | 107.19% | 42.72% | -62.08% | Upgrade |
Shares Outstanding (Basic) | 47 | 47 | 45 | 42 | 43 | 43 | Upgrade |
Shares Outstanding (Diluted) | 48 | 49 | 45 | 42 | 44 | 43 | Upgrade |
Shares Change (YoY) | -0.21% | 6.83% | 7.58% | -4.09% | 2.33% | -1.14% | Upgrade |
EPS (Basic) | 3.14 | 2.94 | 1.11 | 2.97 | 1.38 | 0.98 | Upgrade |
EPS (Diluted) | 3.08 | 2.88 | 1.09 | 2.94 | 1.36 | 0.98 | Upgrade |
EPS Growth | 30.07% | 164.22% | -62.92% | 116.18% | 38.78% | -61.42% | Upgrade |
Free Cash Flow | 169.8 | 176.1 | 189.4 | 21.2 | 78.1 | 182.2 | Upgrade |
Free Cash Flow Per Share | 3.52 | 3.63 | 4.17 | 0.50 | 1.77 | 4.24 | Upgrade |
Dividend Per Share | 1.330 | 1.310 | 1.280 | 1.270 | 1.235 | 1.220 | Upgrade |
Dividend Growth | 3.10% | 2.34% | 0.79% | 2.83% | 1.23% | 0.83% | Upgrade |
Gross Margin | 41.40% | 41.10% | 39.00% | 35.72% | 35.02% | 36.88% | Upgrade |
Operating Margin | 9.06% | 8.62% | 7.28% | 5.09% | 4.55% | 5.15% | Upgrade |
Profit Margin | 5.73% | 5.52% | 2.02% | 5.25% | 2.74% | 2.14% | Upgrade |
Free Cash Flow Margin | 6.58% | 6.97% | 7.78% | 0.90% | 3.57% | 9.32% | Upgrade |
EBITDA | 320.1 | 305.2 | 250.6 | 180.1 | 158.9 | 159.1 | Upgrade |
EBITDA Margin | 12.40% | 12.08% | 10.30% | 7.63% | 7.27% | 8.14% | Upgrade |
D&A For EBITDA | 86.1 | 87.4 | 73.3 | 59.8 | 59.5 | 58.4 | Upgrade |
EBIT | 234 | 217.8 | 177.3 | 120.3 | 99.4 | 100.7 | Upgrade |
EBIT Margin | 9.06% | 8.62% | 7.28% | 5.09% | 4.55% | 5.15% | Upgrade |
Effective Tax Rate | 23.04% | 22.20% | 24.07% | 15.37% | 23.63% | 22.98% | Upgrade |
Updated Jul 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.